153 related articles for article (PubMed ID: 7768562)
1. Antihypertensive effects of a novel endothelin-A receptor antagonist in rats.
Bird JE; Moreland S; Waldron TL; Powell JR
Hypertension; 1995 Jun; 25(6):1191-5. PubMed ID: 7768562
[TBL] [Abstract][Full Text] [Related]
2. Effect of chronic ETA-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats.
Schiffrin EL; Turgeon A; Deng LY
Br J Pharmacol; 1997 Jul; 121(5):935-40. PubMed ID: 9222550
[TBL] [Abstract][Full Text] [Related]
3. A role for endothelin ETA receptors in regulation of renal function in spontaneously hypertensive rats.
Bird JE; Webb ML; Giancarli MR; Chao C; Dorso CR; Asaad MM
Eur J Pharmacol; 1995 Dec; 294(1):183-9. PubMed ID: 8788430
[TBL] [Abstract][Full Text] [Related]
4. Antihypertensive effects of BQ-123, a selective endothelin ETA receptor antagonist, in spontaneously hypertensive rats treated with DOCA-salt.
Okada M; Fukuroda T; Shimamoto K; Takahashi R; Ikemoto F; Yano M; Nishikibe M
Eur J Pharmacol; 1994 Jul; 259(3):339-42. PubMed ID: 7982465
[TBL] [Abstract][Full Text] [Related]
5. Antihypertensive effect of an endothelin receptor antagonist in DOCA-salt spontaneously hypertensive rats.
Schiffrin EL; Sventek P; Li JS; Turgeon A; Reudelhuber T
Br J Pharmacol; 1995 Aug; 115(8):1377-81. PubMed ID: 8564194
[TBL] [Abstract][Full Text] [Related]
6. Hemodynamic effects of a selective endothelin--a receptor antagonist in deoxycorticosterone acetate-salt hypertensive rats.
Yu M; Gopalakrishnan V; McNeill JR
J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S262-4. PubMed ID: 9595455
[TBL] [Abstract][Full Text] [Related]
7. Different activation of vascular mitogen-activated protein kinases in spontaneously and DOCA-salt hypertensive rats.
Kubo T; Ibusuki T; Saito E; Kambe T; Hagiwara Y
Eur J Pharmacol; 2000 Jul; 400(2-3):231-7. PubMed ID: 10988339
[TBL] [Abstract][Full Text] [Related]
8. BQ-123, a selective endothelin subtype A-receptor antagonist, lowers blood pressure in different rat models of hypertension.
Douglas SA; Gellai M; Ezekiel M; Ohlstein EH
J Hypertens; 1994 May; 12(5):561-7. PubMed ID: 7930556
[TBL] [Abstract][Full Text] [Related]
9. Renoprotective effects of a combined endothelin type A/type B receptor antagonist in experimental malignant hypertension.
Kohno M; Yokokawa K; Yasunari K; Kano H; Minami M; Ueda M; Tatsumi Y; Yoshikawa J
Metabolism; 1997 Sep; 46(9):1032-8. PubMed ID: 9284892
[TBL] [Abstract][Full Text] [Related]
10. Antihypertensive actions of the novel nonpeptide endothelin receptor antagonist SB 209670.
Douglas SA; Gellai M; Ezekiel M; Feuerstein GZ; Elliott JD; Ohlstein EH
Hypertension; 1995 Apr; 25(4 Pt 2):818-22. PubMed ID: 7721437
[TBL] [Abstract][Full Text] [Related]
11. Effects of endothelin in radiocontrast-induced nephropathy in rats are mediated through endothelin-A receptors.
Bird JE; Giancarli MR; Megill JR; Durham SK
J Am Soc Nephrol; 1996 Aug; 7(8):1153-7. PubMed ID: 8866406
[TBL] [Abstract][Full Text] [Related]
12. Effect of chronic treatment with two different ET(A) selective endothelin receptor antagonists on blood pressure and small artery structure of deoxycorticosterone acetate (DOCA)-salt hypertensive rats.
Li JS; Turgeon A; Schiffrin EL
Am J Hypertens; 1998 May; 11(5):554-62. PubMed ID: 9633791
[TBL] [Abstract][Full Text] [Related]
13. ETA receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension.
Callera GE; Touyz RM; Teixeira SA; Muscara MN; Carvalho MH; Fortes ZB; Nigro D; Schiffrin EL; Tostes RC
Hypertension; 2003 Oct; 42(4):811-7. PubMed ID: 12913063
[TBL] [Abstract][Full Text] [Related]
14. Endothelin and endothelin antagonists in hypertension.
Schiffrin EL
J Hypertens; 1998 Dec; 16(12 Pt 2):1891-5. PubMed ID: 9886874
[TBL] [Abstract][Full Text] [Related]
15. Antihypertensive effects of a mixed endothelin-A- and -B-receptor antagonist, J-104132, were augmented in the presence of an AT1 -receptor antagonist, MK-954.
Ikeda T; Ohta H; Okada M; Kawai N; Nakao R; Siegl PK; Kobayashi T; Miyauchi T; Nishikibe M
J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S337-41. PubMed ID: 11078414
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure.
Trippodo NC; Robl JA; Asaad MM; Bird JE; Panchal BC; Schaeffer TR; Fox M; Giancarli MR; Cheung HS
J Pharmacol Exp Ther; 1995 Nov; 275(2):745-52. PubMed ID: 7473162
[TBL] [Abstract][Full Text] [Related]
17. BMS-182874 is a selective, nonpeptide endothelin ETA receptor antagonist.
Webb ML; Bird JE; Liu EC; Rose PM; Serafino R; Stein PD; Moreland S
J Pharmacol Exp Ther; 1995 Mar; 272(3):1124-34. PubMed ID: 7891325
[TBL] [Abstract][Full Text] [Related]
18. ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats.
Park JB; Schiffrin EL
Hypertension; 2001 Jun; 37(6):1444-9. PubMed ID: 11408393
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization of PABSA, an orally active and highly potent endothelin-receptor antagonist.
Iwasaki T; Mihara S; Shimamura T; Kawakami M; Hayasaki-Kajiwara Y; Naya N; Fujimoto M; Nakajima M
J Cardiovasc Pharmacol; 1999 Jul; 34(1):139-47. PubMed ID: 10413080
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension.
Trensz F; Bortolamiol C; Kramberg M; Wanner D; Hadana H; Rey M; Strasser DS; Delahaye S; Hess P; Vezzali E; Mentzel U; Ménard J; Clozel M; Iglarz M
J Pharmacol Exp Ther; 2019 Mar; 368(3):462-473. PubMed ID: 30622171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
